Overview

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

Phase:

Phase 1

Details

Lead Sponsor:

University of Rochester

Collaborators:

Bristol-Myers Squibb
Syntrix Biosystems, Inc.

Treatments:

Nivolumab